Scope of cardiovascular complications in patients with kidney disease

Ethnicity and Disease

Volumn 12, Issue 4, 2002, Pages

  McCullough, Peter A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Chronic kidney disease; End stage renal disease; Heart failure; Microalbuminuria; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT;

ACUTE KIDNEY FAILURE; ANALYTIC METHOD; ANGIOPLASTY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DISEASE ASSOCIATION; DISEASE COURSE; HEART ATRIUM ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; KIDNEY DISEASE; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 0036762968     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Lewis CE, Jacobs DR Jr, McCreath H, et al. Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol. June 15, 2000;151(12):1172-1181.
2. Bretzel RG. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens. Sept 1997;10(9, pt 2):208S-217S.
3. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in Coronary Care Unit patients. J Am Coll Cardiol. 2000;36(3):679-684.
4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol. 2002;39:60-69.
5. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, McCullough PA. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001;37:1191-2000.
6. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis. June 2000; 35(6):1044-1051.
7. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998;128:194-203.
8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
9. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation. 1997;95:878-884.
10. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28:557-563.
11. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. Nov 1998;32(5):853-906.
12. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: part 4: definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39(suppl 1):S46-S75.
13. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. May 1999;33(5):1004-1010.
14. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. Nov 1996; 50(5):1651-1658.
15. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. April 24, 2000;160(8):1093-1100.
16. Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med. Sept 28, 1998;158(17):1933-1939.
17. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med. Oct 17, 2000;133(8):585-591.
18. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. Nov 24, 1997;157(21):2413-2446.
19. Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7:107-117.
20. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from cyclooxygenase inhibition. J Clin Invest. 1987;79:1788-1797.
21. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in northeastern United States. J Am Soc Nephrol. 2001;12:1501-1507.
22. Brenner BM, Cooper ME, de Zeeuw D, et al, and the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. Sept 20, 2001;345(12):861-869.
23. Lewis EJ, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. Sept 20, 2001;345(12):851-860.
24. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. Sept 20, 2001;345(12):870-878.
25. Dahlof B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. March 23, 2002; 359(9311):995-1003.
26. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. June 1, 2001;37(7):1775-1780.